Olink Holding AB (publ) announced that deCODE genetics will have internal access to the Olink Explore 3072 platform, comprised of approximately 3,000 high quality protein assays with a Next Generation Sequencing read-out. Through an agreement between the two companies, deCODE genetics will be one of the first companies to adopt and internalize the new Explore 3072 proteomics platform and will act as an early testing site for its use. In doing so, deCODE and Olink will work together to optimize Olink’s high throughput, high-quality proteomics to its population scale efforts of advancing modern healthcare. Based in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE genetics has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. Olink intends to make the Olink Explore 3072 high quality protein assay platform broadly available in the fourth quarter of 2021.